Urolog. pro Praxi, 2006; 3: 112-116

URGE URINARY INCONTINENCE - TODAY´S STATUS OF OCCURRENCE, DIAGNOSIS AND THERAPY

MUDr. Jozef Marenčák Ph.D
Urologické oddelenie NsP Skalica

In the form of summary survey, the autor of this report addreesses the urge urinary incontinence (UUI). Overactive bladder (OAB) is characterised by urgency and/ or urge incontinence (UI) – OAB dry or OAB wet – usually with freqency (more than 8 times/ day and more than 2 times/ night), in the absence of local pathological or endocrine factors. OAB is a highly prevalent, debilitating, and costly condition which has a negative impact on the patients´ quality of life. Author briefly reported about epidemiology, (possible) etiology and pathophysiology, diagnosis and therapy OAB. Anticholenrgic agents are the medication of first choice, but they often have limitations due to side effects such as dry mouth. There were discussed another eventualities and perspectives (mostly) of conservative treatment of OAB.

Keywords: urge urinary incontinence, overactive bladder, epidemiology, diagnosis, therapy

Published: August 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. URGE URINARY INCONTINENCE - TODAY´S STATUS OF OCCURRENCE, DIAGNOSIS AND THERAPY. Urol. praxi. 2006;7(3):112-116.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P. Urodynamics. London: Springer - Verlag, 1997, 341 s. Go to original source...
    2. Abrams P, Cardozo L, Fall M. et al. The standardisation of terminology of lower tract function: report from the standardisation sub - committeee of the International Continence Society. Neurourol and Urodyn, 21, 2002, č. 5, s. 1670-1678. Go to original source... Go to PubMed...
    3. Abrams P, Wein J. The impact of overactive bladder on patients and society, and current approaches to treatment. Institute for medical studies, 2002, 16 s.
    4. Andersson K, Takeda M, Abrams P. Lower urinary tract symptoms 2002 - an update on storage and voiding symptoms. 26 th Congress of the Société Internationale d´Urologie, Sept. 10, 2002. Abstract books, s. 1-12.
    5. Appell R, Sand P, Dmochowski R. et al. Prospective randomised controlled trial of extended - release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of OBJECT study. Mayo Clin. Proc., 76, 2001, č. 2, s. 358-363. Go to original source...
    6. Artibani W. Overactive bladder: new perspectives. Eur. Urol., 1, 2002, Suppl. 4, s. 1-30. Go to original source...
    7. Balken R, Vandonick V, Gisolf K. et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunctions. J. Urol., 166, 2001, č. 4, s. 914-918. Go to original source... Go to PubMed...
    8. Berghmans L, Hendriks H, De Bie, R. et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int., 85, 2000, č. 2, s. 254-263. Go to original source... Go to PubMed...
    9. Breza J, Alemayehu H, Vávrová D. et al. Princípy kontinentnej derivácie moču. Lek. Obzor, 40, 1991, č. 5, s. 377-390.
    10. Cardozo L, Staskin D, Kirby M. Urinary incontinence in primary care. Oxford: Issis Medical media Ltd., 2000, 136 s.
    11. Collas D, Mallone - Lee J. The pharmacokinetic properties of rectal oxybutynin a possible alternative to intravesical administration. Neurourol. Urodyn., 16, 1997, č. 4, s. 346-347.
    12. Diokno A, Appell R, Sand P. et al. Prospective, randomised, double - blind study of the efficacy and tolerabilty of the extended - release formulations of oxybutynin and tolterodine for overactive bladder. Results of the OPERA trial. Mayo Clin. Proc., 78, 2003, č. 4, s. 687-695. Go to original source... Go to PubMed...
    13. Dúbravický J, Marenčák J, Moro R. Odhad prevalencie inkontinencie moču a spôsobu jej liečby v náhodne vybratej vzorke dospelej populácie na Slovensku. Urológia, 8, 2002, suppl. 1, s. 1-11.
    14. Gillespie J. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int., 93, 2004, č. 2, s. 478-483. Go to original source... Go to PubMed...
    15. Goldberg R, Sand P. Pathophysiology of the overactive bladder. Clin. Obstet. Gynecol., 45, 2002, č. 1, s. 182-192. Go to original source... Go to PubMed...
    16. Hanuš T. Poruchy mikce. Praha: ILF, 1991, s. 21-22.
    17. Höffner K. Therapie der überaktiven Blase mit Antimuskarinika. Der Urologe A, 42, 2003, č. 6, s. 793-800. Go to original source... Go to PubMed...
    18. Hunskaar S, Burgio K, Diokno A. et al. Epidemiology and natural history of urinary incontinence. In: Abrams P, Cardozo L, Khoury S. et al. Incontinence. 2nd International Consultation on Incontinence. Plymouth: Health Publ. Ltd., 2002, s. 165-201.
    19. Chancellor M, de Groat W. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J. Urol., 162, 1999, č. 2, s. 3-11. Go to original source... Go to PubMed...
    20. Chapple C, Arano P, Bosch J, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo and tolterodine - controlled phase 2 dose - finding study. BJU Int., 93, 2004, č. 1, s. 71-77. Go to original source... Go to PubMed...
    21. Chapple C, Rechberger T, Al - Shukri S. et al. randomized, double - blind placebo and tolterodin - controlled trial of the once - daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int., 93, 2004, č. 3, s. 303-310. Go to original source... Go to PubMed...
    22. Johnson T, Kincade J, Bernard S. et al. Self - care practices used by older men and women to manage urinary incontinence: results from the National Follow - up Survey on Self - Care and Aging. J. Am. Geriatr. Soc., 48, 2000, č. 4, s. 894-902. Go to original source... Go to PubMed...
    23. Marenčák J. Diagnostika a liečba hyperaktívneho močového mechúra. Lek listy (príloha ZdN), 2003, č. 30, s. 18-22.
    24. Marenčák J. Hyperaktívny močový mechúr: For. Med. speciál, 6, 2003, s. 9.
    25. Marenčák J. Medikamentózna liečba hyperaktívneho močového mechúra. Lek listy (príloha ZdN), 9, 2004, č. 4, s. 31-34.
    26. Michel M. Neue pharmakologische Therapiekonzepte bei überaktiver Blase. Der Urologe A, 42, 2003, č. 30, s. 807-811. Go to original source... Go to PubMed...
    27. Milsom I, Abrams P, Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int., 87, 2001, č. 3, s. 760. Go to original source... Go to PubMed...
    28. Quin P, Goka J, Richardson H. Assessment of an electronic diary in patients with overactive bladder. BJU Int., 91, 2003, č. 3, s. 647-652. Go to original source... Go to PubMed...
    29. Shah J. Female urinary incontinence. In Shah, J., Urology highlights 2002-2003. Health Press Limited, Oxford 2003, s. 74-85. Go to original source...
    30. Stoller M. Afferent nerve stimulation for pelvic floor dysfunction. Eur. Urol., 35, 1999, č. 1., suppl. 1., 16-20.
    31. Švihra J. Hyperaktívny močový mechúr. Urologická akadémia, 2004, lekcia 4, 12 s.
    32. Švihra J, Baška T, Martin M. et al. Prevalence of female overactive bladder with urinary incontinence in Slovakia. Eur. Urol., 2002, suppl. 1, s. 85. Go to original source...
    33. Švihra J, Javorka K, Ľupták J. et al. Non - invasive evaluation of urge incontinence in women. 1st International Consultation on Incontinence, Monaco 1998, Abstract book, s. 51.
    34. Švihra J, Kurca E, Ľupták J. et al. Neuromodulative treatment of overactive bladder - noninvasive tibial nerve stimulation. Bratisl. Lek. Listy, 103, 2002, č. 4, s. 480-483.
    35. Walsh I, Johnston R, Keane P. Transcutaneous sacral neurostimulation for irritative voiding dysfunction. Eur. Urol., 35, 1999, č. 1, s. 192-196. Go to original source... Go to PubMed...
    36. Wyndaele J. Overactive bladder: reviewing the evidence. Eur. Urol., 2, 2003, Suppl. 5, s. 1-22. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.